HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
NR2E3
nuclear receptor subfamily 2 group E member 3
Chromosome 15 Β· 15q23
NCBI Gene: 10002Ensembl: ENSG00000278570.5HGNC: HGNC:7974UniProt: F1D8Q9
69PubMed Papers
22Diseases
0Drugs
152Pathogenic Variants
FUNCTIONAL ROLE
ReceptorTranscription Factor
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
sequence-specific DNA bindingDNA-binding transcription activator activity, RNA polymerase II-specificpositive regulation of transcription by RNA polymerase IIprotein bindingenhanced S-cone syndromeretinitis pigmentosa 37retinitis pigmentosaGoldmann-Favre syndrome
✦AI Summary

NR2E3 is an orphan nuclear receptor transcription factor essential for rod photoreceptor development and function in the retina. 1 As a transcriptional activator, NR2E3 promotes rod-specific gene expression, including rhodopsin and rod phosphodiesterase, while simultaneously repressing cone-specific genes such as M- and S-opsin. 1 NR2E3 operates in concert with other transcription factors like NRL to establish proper photoreceptor identity during retinal development. 1 Loss of NR2E3 function causes rod precursor cells to misdifferentiate into cells with hybrid rod-cone characteristics or S-cone-like phenotypes, resulting in absent rod function and abnormally elevated short-wavelength light sensitivity. 2 Pathogenic NR2E3 variants cause a spectrum of inherited retinal dystrophies, primarily Enhanced S-cone Syndrome (ESCS), Retinitis Pigmentosa 37, and Goldmann-Favre syndrome. 1 3 ESCS is characterized by night blindness due to rod dysfunction, though early-stage visual acuity may remain relatively preserved. 2 Human organoid studies reveal that NR2E3 loss disrupts normal photoreceptor maturation and causes misexpression of cone-specific phototransduction genes in rods, with disease manifestations differing significantly from rodent models. 4 Progressive disease leads to characteristic retinal changes including macular schisis and periarcuate retinal degeneration. 5 6 Emerging therapeutic approaches, including gene therapy and gene editing, show promise for treating NR2E3-related retinopathies. 1

Sources cited
1
NR2E3 is required for proper expression of phototransduction genes including rhodopsin in developing rods, and NR2E3-null rods misexpress cone-specific genes
PMID: 38652563
2
Enhanced S-cone syndrome is associated with NR2E3 mutations and is a form of inherited retinal disease
PMID: 38278208
3
NR2E3 variants cause macular schisis, retinal degeneration around vascular arcades, and distinct clinical presentations in autosomal dominant versus recessive forms
PMID: 37628579
4
NR2E3 is required for rod photoreceptor development, suppresses cone-specific genes, activates rod-specific genes in concert with NRL, and pathogenic variants cause multiple retinopathy phenotypes
PMID: 37510230
5
Enhanced S-cone syndrome results from NR2E3 variants causing rod precursors to form S-cone-like photoreceptors, resulting in night blindness and enhanced short-wavelength sensitivity
PMID: 37440033
6
NR2E3 mutations cause abnormal retinal laminar architecture with thickened and bulging retinal appearance at disease progression stages
PMID: 15229190
Disease Associationsβ“˜22
enhanced S-cone syndromeOpen Targets
0.82Strong
retinitis pigmentosa 37Open Targets
0.77Strong
retinitis pigmentosaOpen Targets
0.71Strong
Goldmann-Favre syndromeOpen Targets
0.62Moderate
Retinal dystrophyOpen Targets
0.57Moderate
Joubert syndrome and related disordersOpen Targets
0.52Moderate
retinopathyOpen Targets
0.43Moderate
Cone rod dystrophyOpen Targets
0.43Moderate
autosomal recessive retinitis pigmentosaOpen Targets
0.42Moderate
Posterior column ataxia - retinitis pigmentosaOpen Targets
0.42Moderate
cone-rod dystrophyOpen Targets
0.42Moderate
genetic disorderOpen Targets
0.42Moderate
eye diseaseOpen Targets
0.37Weak
inherited retinal dystrophyOpen Targets
0.37Weak
Visual impairmentOpen Targets
0.37Weak
Color vision defectOpen Targets
0.34Weak
Horizontal nystagmusOpen Targets
0.34Weak
ocular albinismOpen Targets
0.34Weak
Leber congenital amaurosisOpen Targets
0.33Weak
Abnormality of the eyeOpen Targets
0.26Weak
Enhanced S cone syndromeUniProt
Retinitis pigmentosa 37UniProt
Pathogenic Variants152
NM_014249.4(NR2E3):c.119-2A>CPathogenic
Enhanced S-cone syndrome|not provided|Retinitis pigmentosa 37|NR2E3-related disorder|Retinal dystrophy|not specified|Retinal dystrophy;Color vision defect;Horizontal nystagmus;Visual impairment|Cone-rod dystrophy|Retinitis pigmentosa 37;Enhanced S-cone syndrome|Retinitis pigmentosa|Ocular albinism|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026
NM_014249.4(NR2E3):c.481del (p.Thr161fs)Pathogenic
Retinitis pigmentosa|not provided|Retinal dystrophy|Enhanced S-cone syndrome|NR2E3-related disorder|Retinitis pigmentosa 37
β˜…β˜…β˜†β˜†2026β†’ Residue 161
NM_014249.4(NR2E3):c.932G>A (p.Arg311Gln)Pathogenic
Enhanced S-cone syndrome|Goldmann-Favre syndrome|not provided|NR2E3-related disorder|Retinitis pigmentosa|Enhanced S-cone syndrome;Retinitis pigmentosa 37|Retinal dystrophy|Autosomal recessive retinitis pigmentosa|Enhanced S-cone syndrome;NR2E3-related disorder|Retinitis pigmentosa 37
β˜…β˜…β˜†β˜†2026β†’ Residue 311
NM_014249.4(NR2E3):c.364C>T (p.Arg122Cys)Pathogenic
Retinitis pigmentosa|Enhanced S-cone syndrome;Retinitis pigmentosa 37|Retinal dystrophy|not provided|Enhanced S-cone syndrome|NR2E3-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 122
NM_014249.4(NR2E3):c.1095C>G (p.Pro365=)Pathogenic
not provided|Enhanced S-cone syndrome|NR2E3-related disorder|Retinal dystrophy
β˜…β˜…β˜†β˜†2026β†’ Residue 365
NM_014249.4(NR2E3):c.226C>T (p.Arg76Trp)Pathogenic
Enhanced S-cone syndrome|not provided|Retinitis pigmentosa|NR2E3-related disorder|Retinal dystrophy
β˜…β˜…β˜†β˜†2026β†’ Residue 76
NM_014249.4(NR2E3):c.305C>A (p.Ala102Asp)Pathogenic
Abnormality of the eye|Retinal dystrophy|not provided|Enhanced S-cone syndrome|Retinitis pigmentosa 37|Retinitis pigmentosa 37;Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2026β†’ Residue 102
NM_014249.4(NR2E3):c.227G>A (p.Arg76Gln)Pathogenic
Enhanced S-cone syndrome|NR2E3-related disorder|Retinitis pigmentosa 37;Enhanced S-cone syndrome|not provided|Retinal dystrophy|Goldmann-Favre syndrome|Retinitis pigmentosa 37
β˜…β˜…β˜†β˜†2025β†’ Residue 76
NM_014249.4(NR2E3):c.311G>A (p.Arg104Gln)Pathogenic
Retinal dystrophy|Retinitis pigmentosa|not provided|Retinitis pigmentosa 37|Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 104
NM_014249.4(NR2E3):c.724_725del (p.Ser242fs)Pathogenic
Cone-rod dystrophy|not provided|Enhanced S-cone syndrome|Retinal dystrophy|Enhanced S-cone syndrome;Retinitis pigmentosa 37
β˜…β˜…β˜†β˜†2025β†’ Residue 242
NM_014249.4(NR2E3):c.612_642del (p.Pro205fs)Pathogenic
not provided|Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 205
NM_014249.4(NR2E3):c.352G>A (p.Val118Met)Likely pathogenic
Retinitis pigmentosa|not provided|Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 118
NM_014249.4(NR2E3):c.1025T>C (p.Val342Ala)Likely pathogenic
not provided|Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 342
NM_014249.4(NR2E3):c.309C>A (p.Cys103Ter)Pathogenic
Retinal dystrophy|not provided|Retinitis pigmentosa 37|Enhanced S-cone syndrome|Retinitis pigmentosa 37;Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 103
NM_014249.4(NR2E3):c.310C>T (p.Arg104Trp)Pathogenic
not provided|Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 104
NM_014249.4(NR2E3):c.166G>A (p.Gly56Arg)Pathogenic
Retinitis pigmentosa 37|not provided|Retinitis pigmentosa|Retinal dystrophy|Retinal disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 56
NM_014249.4(NR2E3):c.406G>T (p.Glu136Ter)Pathogenic
not provided|Retinal dystrophy|Retinitis pigmentosa|Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 136
NM_014249.4(NR2E3):c.874del (p.Arg292fs)Pathogenic
not provided|Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 292
NM_014249.4(NR2E3):c.194_202del (p.Asn65_Cys67del)Pathogenic
Retinitis pigmentosa 37;Enhanced S-cone syndrome|Retinitis pigmentosa|Retinal dystrophy|not provided|Enhanced S-cone syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 65
NM_014249.4(NR2E3):c.373C>T (p.Arg125Ter)Pathogenic
not provided|Retinitis pigmentosa 37|Enhanced S-cone syndrome|Enhanced S-cone syndrome;Retinitis pigmentosa 37|Retinal dystrophy
β˜…β˜…β˜†β˜†2025β†’ Residue 125
View on ClinVar β†—
Related Genes
ARR3Protein interaction97%CRXProtein interaction97%RCVRNProtein interaction97%RPE65Protein interaction97%EYSProtein interaction86%PDE6BProtein interaction85%
Tissue Expression6 tissues
Liver
100%
Lung
73%
Brain
29%
Ovary
21%
Bone Marrow
4%
Heart
0%
Gene Interaction Network
Click a node to explore
NR2E3ARR3CRXRCVRNRPE65EYSPDE6B
PROTEIN STRUCTURE
Preparing viewer…
PDB4LOG Β· 2.70 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.47LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF1.12 [0.86–1.47]
RankingsWhere NR2E3 stands among ~20K protein-coding genes
  • #6,826of 20,598
    Most Researched69
  • #502of 5,498
    Most Pathogenic Variants152 Β· top 10%
  • #14,985of 17,882
    Most Constrained (LOEUF)1.47
Genes detectedNR2E3
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
NR2E3 loss disrupts photoreceptor cell maturation and fate in human organoid models of retinal development.
PMID: 38652563
J Clin Invest Β· 2024
1.00
2
PMID: 20301590
0.90
3
Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes.
PMID: 38278208
Prog Retin Eye Res Β· 2024
0.80
4
Interspecies Correlations between Human and Mouse
PMID: 33513943
J Clin Med Β· 2021
0.70
5
Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.
PMID: 27294413
Hum Genomics Β· 2016
0.60